Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel
Tuesday, 8 October 2024
Dr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene autoleucel, following promising phase-1 results showing significant clinical response in patients with relapsed or refractory multiple myeloma.
|
||||
|
|
||||
You Might Like |
||||
